Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG

Tumori

Volumn 84, Issue 3, 1998, Pages 335-347

  Wils, Jacques ^a   Sahmoud, Tarek ^b,y   Sobrero, Alberto ^c   Bleiberg, Harry ^d   Ahmedzai, Sam ^e   Blazeby, Jane ^f   Blijham, Geert ^g   Conroy, Thierry ^h   Cunningham, David ⁱ   Curran, Desmond ^b,y   Díaz Rubio, Eduardo ^j   Ducreux, Michel ^k   Evans, Jeff ^l   Glimelius, Bengt ^m   Hutchinson, Gillian ⁿ   Kerr, David ^o   Kiebert, Gwendoline ^b,y   Köhne, Hennig ^p   Labianca, Roberto ^q   Langendijk, Rina ^a   Nitti, Donato ^r   Nordlinger, Bernard ^s   Rougier, Philippe ^s   Scheithauer, Werner ^t   Schmoll, Hans Joachim ^u   Van Cutsem, Eric ^v   Wagener, Theo ^w   Wilke, Jochen ^x   Marinus, Ann ^b,y   Therasse, Patrick ^b,y   more..

^a LAURENTIUS HOSPITAL   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF UDINE   (Italy)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f BRISTOL ROYAL INFIRMARY   (United Kingdom)

^g AZ Utrecht   (Netherlands)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l WESTERN INFIRMARY   (United Kingdom)

^m UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁿ ST GEORGE S HOSPITAL   (United Kingdom)

^o QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^p Section of Pathology   (Germany)

^q OSPEDALI RIUNITI   (Italy)

^r UNIVERSITY OF PADOVA   (Italy)

^s HÔPITAL AMBROISE PARÉ   (France)

^t UNIVERSITY OF VIENNA   (Austria)

^u MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^v UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^w RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^x UNIVERSITY HOSPITAL ESSEN   (Germany)

^y Zeneca Medical Department   (Belgium)

more..

Author keywords

Advanced colorectal cancer; Endpoints of medical treatment

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; OXALIPLATIN; RALTITREXED; TEGAFUR; URACIL;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION;

EID: 0031837358     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400306     Document Type: Review

References (79)

1. Aaronson N.K., Ahmedzai S., Bergman B., et al.: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst., 85: 365-376, 1993.
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by folinic acid in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
3. Allen-Mersh T.G., Earlam S., Fordy C.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet, 344: 1255-1260, 1994.
4. American Society of Clinical Oncology: Outcome of cancer treatment for technology assessment and cancer treatment guidelines. J. Clin. Oncol., 14: 671-679, 1996.
5. Andersen J.S., Burris H.A., Casper E., et al: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 13: 461 (abstr 1600), 1994.
6. Anderson J.R., Cain K.C., Gelber R.D.: Analysis of survival by tumor response. J. Clin. Oncol., 1: 710-719, 1983.
7. Aranda E., Cervantes A., Anton A., et al: A phase III multicenter randomized study in advanced colorectal cancer: fluorouracil high dose continuous infusion weekly versus fluorouracil + leucovorin. Preliminary results. Proc. Am. Soc. Clin. Oncol., 16: 281a, 1997.
8. Bécouarn Y., Ychou M., Ducreux M., et al: Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc. Am. Soc. Clin. Oncol., 16: 229a, 1997.
9. Beretta G., Bollina R., Cozzi C., et al.: Should we consider the weekly (w) chemotherapy (CT) with fluorouracil (F) + racemin folinic acid (f) a standard treatment for advanced/metastatic carcinoma of the digestive tract (DTC) in elderly patients (pts)? Proc. Am. Soc. Clin. Oncol., 16, 259a (abstr), 1997.
10. Bleiberg H.: Colorectal cancer. Is there an alternative to 5-FU? Eur. J. Cancer, 33: 536-541, 1997.
11. Blijham G., Wagener T., Wils J., et al: Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer. Final results of a randomized European Organisation for Research and Treatment of Cancer study. J. Clin. Oncol., 14: 2266-2273, 1996.
12. Brienza S., Vignoud J., Itzhaki M., Krikorian A.: Oxaliplatin (L-OHP): global safety in 682 patients (pts). Proc. Am. Soc. Clin. Oncol., 14: 209 (abstr), 1995.
13. Burris H.A., Moore M.J., Andersen J., et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15, 2403-2413, 1997.
14. Buter J., Sinnige H.A., Cats A., et al.: Maintenance of remission on 5-fluorouracil (5-FU), leucovorin (LV) and alpha-2A interferon (IFN alpha) in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 13: (abstr 557), 1994.
15. Buyse M., Piedbois P.: On the relationship between response to treatment and survival time. Stats. Med., 15: 2797-2812, 1996.
16. Caudry M., Bonnel C., Floquet A., et al.: A randomized study of bolus fluorouracil plus folinic acid versus 21 day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am. J. Clin. Oncol., 18: 118-125, 1995.
17. Cella D.F., Tulsky D.S., Gray G., et al.: The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol., 11: 570-579, 1993.
18. Cella D.F., Tulsky D.S.: Measuring quality of life today: methodological aspects. Oncology, 4: 29-38, 1990.
19. Chu D.Z., Rikson C.A., Russell M.P., et al.: Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch. Surg., 126: 314-316, 1991.
20. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol., 14: 2843-2877, 1996.
21. Cunningham D., Zalcberg J., Rath U., et al: Final results of a randomised trial comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol., 7: 961-965, 1996.
22. Cunningham D., Zalcberg J.R., Rath U., et al.: Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The Tomudex Colorectal Cancer Study Group. Eur. J. Cancer, 31A: 1945-1954, 1995.
23. De Gramont A., Bosset J.F., Milan C., et al: Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusions for advanced colorectal cancer. A French Intergroup Study. J. Clin. Oncol., 15: 808-815, 1997.
24. de Gramont A., Vignoud J., Tournigand C., et al.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
25. De Haes J.C.J.M., van Knippenberg F.C.E., Neijt J.P.: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Check-List. Br. J. Cancer, 62: 1034-1038, 1990.
26. Fages B., Cote C., Gruia G., et al.: Tumor response and stabilization rates are worthwhile surrogate efficacy endpoints in metastatic colorectal cancer. Analysis of data in 455 5-FU resistant patients treated with CPT11 (in preparation).
27. Fallowfield L.: Quality of quality of life data. Lancet, 348: 421, 1996.
28. Fielding L.P., Pettigrew N.: College of American Pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch. Pathol. Lab. Med., 119: 1115-1121, 1995.
29. Findlay M., Van Cutsem E., Kocha W., et al.: A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Am. Soc. Clin. Oncol., 16: 227a, 1997.
30. Giacchetti S., Zidani R., Perpoint B., et al.: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol., 16: 229a, 1997.
31. Glimelius B., Hoffman K., Graf W., et al: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer, 73: 556-562, 1994.
32. Glimelius B., Hoffman K., Olafdottir M., et al.: Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. Eur. J. Cancer Clin. Oncol., 25: 829-835, 1989.
33. Graf W., Pahlman L., Bergstrom R., Glimelius B.: The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br. J. Cancer, 70: 559-563, 1994.
34. Grill R., Oxman A.D., Julian J.A.: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J. Clin. Oncol., 11: 1866-1872, 1993.
35. Hejna M., Kornek G., Weinl‰nder G., et al.: Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Acta Chir. Austr., Suppl 115: 52, 1995.
36. Howell A., Mackintosh J., Jones M., et al.: The definition of the "No Change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur. J. Cancer Clin. Oncol., 24: 1557-1572, 1996.
37. Jäger E., Heike M., Bernhard H., et al.: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J. Clin. Oncol., 14: 2274-2279, 1996.
38. Johnson J.R., Temple R.: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat. Rep., 69: 1155-1159, 1985.
39. Köhne C., Schöffski P., Wilke H., et al.: Biochemical modulation of weekly high-dose infusional (HD-CI) 5-FU in patients with advanced colorectal cancer. Results of a multicenter randomized AIO trial. Proc. Am. Soc. Clin. Oncol., 16: 271a, 1997.
40. Köhne C.H., Hecker H., Schöffski P., et al.: Weekly high dose infusional (CI) 5-FU plus folinic acid (FA) has major impact on survival in patients with advanced colorectal cancer. Results of a multivariate analysis using RECPAM. Proc. Am. Soc. Clin. Oncol., 15: 201a, 1996.
41. Köhne C.H., Hiddemann W., Schüller J., et al.: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J. Clin. Oncol., 13: 1201-1208, 1995.
42. Köhne-Wömpner C.H., Schmoll H.F., Harstrick A., Rustum Y.M.: Chemotherapeutic strategies in metastatic colorectal cancer. An overview of current clinical trials. Semin. Oncol., 19: 105-125, 1992.
43. Labianca R., Cascinu S., Frontini L., et al.: High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. Ann. Oncol., 8: 169-174, 1997.
44. Labianca R., Pancera G., Aitini E., et al.: Folinic acid + 5-Fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer). Ann. Oncol., 2: 673-679, 1991.
45. Leichman C.G., Fleming T.R., Muggia F.M., et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J. Clin. Oncol., 13: 1303-1311, 1995.
46. Lévi F.A., Zidani R., Vannetzel J.-M., et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folonic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst., 86: 1608-1617, 1994.
47. Lokich J.J., Ahlgren J.D., Gullo J.J., et al.: A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus administration schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 1989, 7: 425-432.
48. Machover D., Diaz-Rubio E., de Gramont A., et al: Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
49. Meyerowitz B.E.: Quality of life in breast cancer patients. The contribution of data to the care of patients. Eur. J. Cancer., 29A: S 59-62, 1993.
50. Moertel C.G., Fleming T.R., Macdonald J.S., et al.: Fluorouracil plus levamisol as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
51. Nordic Gastrointestinal tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol., 10: 904-911, 1992.
52. O'Leary J.F., Fairclough D.L., Jankowski M.K., et al.: Comparison of time trade off utilities and rating scale values in cancer patients and their relatives. J. Med. Decis. Making, 15: 132-137, 1995.
53. Pazdur R., Lassere Y., Rhodes V., et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
54. Pitot H.C., Wender D.B., O'Connell M.J., et al.: Phase II trial of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 15: 2910-2919, 1997.
55. Revicki D.A.: Assessing health related quality of life in clinical trials and practice settings: an overview, pp. 350-355, AS-CO Educational Book, 1997.
56. Ross P., Norman A., Cunningham D., et al.: A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 271a, 1997.
57. Rothenberg M.L., Moore M.J., Cripps M.C., et al.: A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann. Oncol., 7, 347-353, 1996.
58. Rougier P., Bugat R., Douillard J.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
59. Rougier P., Bugat R., Marty M., et al.: Efficacy of CPT-11 in CRC patients progressive on 5-FU-based chemotherapy, p. 97 In: VIth EORTC GITCCG Symposium: an update after 25 years of experience, Nijmegen 1996.
60. Rougier Ph., Paillot B., Laplanche A., et al.: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur. J. Cancer, 33: 1789-1793, 1997.
61. Sahmoud T., Grabowska E., Blijham G., et al.: The identification of high risk patients with metastatic colorectal cancer. Abstr. 9th European Cancer Conference (ECCO 9), Hamburg, September 14-18, 1997.
62. Scheithauer W., Depisch D., Kornek G., et al.: Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer. Cancer, 73: 1562-1568, 1994.
63. Scheithauer W., Kornek G., Marczell A., et al.: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III. J. Clin. Oncol., 15: 908-914, 1997.
64. Scheithauer W., Rosen H., Kornek G.V., et al.: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J., 306: 752-755, 1993.
65. Schipper H., Clinch J., McMurray A., Levitt M.: Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J. Clin. Oncology, 2: 472-483, 1984.
66. Schmoll H.J.: Is there a second line chemotherapy in colorectal cancer? Educational book of the 21st ESMO Congress, Vienna, Austria, November 1-5, 1996, pp. 35-42.
67. Schöffski P., Schellenberger U., Köhne C.H., et al.: Quality of life predicts for both response and survival in patients treated for metastatic colorectal cancer. Results of a randomized phase II study. Proc. Am. Soc. Clin. Oncol., 15: 213, 1996.
68. Schulman K., Johnson A., Rathore S.: The use of satisfaction measures in Oncology. ASCO Educational Book, pp. 337-341, 1997.
69. Smyth J.F., Hardcastle D., Denton G., et al.: Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann. Oncol., 6: 948-949, 1995.
70. Sobrero A., Aschele C., Bertino J.: Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation. J. Clin. Oncol., 15: 368-381, 1997.
71. Stein B.N., Petrelli N.J., Douglass H.O., et al.: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer, 75: 11-17, 1995.
72. Stoffregen C., Zurborn K.H., Boehme V., et al.: Weekly high-dose 5-fluorouracil 24-hours infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer. Oncologie, 19: 410-441, 1996.
73. Torrance G.W.: Measurement of health state utilities for economic appraisal. J. Health Econ., 5: 1-30, 1985.
74. Tsevat J., Weeks J.C., Guadagnoli E., et al: Using health related quality of life information; clinical encounters, clinical trials and health policies. J. Gen. Intern. Med., 9: 576-582, 1994.
75. Van Cutsem E., Rougier Ph., Droz J.P., et al.: Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU. Proc. Am. Soc. Clin. Oncol., 16: 268a, 1997.
76. Van Cutsem E.: A glimpse of the future. New directions in the treatment of colorectal cancer. Eur. J. Cancer, 32A (Suppl 5): S23-27, 1996.
77. Webb A., Scott Mackie P., Cunningham D.: The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann. Oncol., 6: 581-587, 1995.
78. Wils J.A.: High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Sem. Oncol., 19, 2 (suppl 3): 126-130, 1992.
79. Zalcberg J.R., Cunningham D., Van Cutsem E., et al.: Tomudex (ZD1694), a novel thymidylate synthase inhibitor, has substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol., 14: 716-721, 1996.